Company Overview and News

16
TTNP / Titan Pharmaceuticals, Inc. null

2018-06-15 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C0Y(# @;V)J#3P\+TQI;[email protected](O5'EP92]84F5F+U=;,2 R(#%=/CYS=')E86T-"FC>8F)[email protected] M8F#R A(,4X [email protected](")-C#@<2G/PQ,C P'0+(,C.C$?\;)?P "# #5A0?D M#0IE;F1S=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @ M(" @#0HV,2 P(&]B:@T\/"]#(#8Y+T9I;'1E
TTNP

21
TTNP / Titan Pharmaceuticals, Inc. 8-K (Current Report)

2018-06-01 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TTNP

22
TTNP / Titan Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-05-30 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TTNP

17
Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q1 2018 Results - Earnings Call Transcript

2018-05-17 seekingalpha
Thank you for holding and welcome to the Titan Pharmaceuticals First Quarter 2018 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being taped at the company’s request and will be archived on the company’s website starting later today. At this time, I would like to turn the call over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals. Please go ahead.
TTNP GUD KHTRF

21
TTNP / Titan Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-05-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TTNP

19
Horizon Technology Finance's (HRZN) CEO, Robert Pomeroy on Q1 2018 Results - Earnings Call Transcript

2018-05-02 seekingalpha
Good morning and welcome to Horizon Technology Finance’s first quarter 2017 conference call. Today’s call is being recorded. All lines have been placed on mute. We will conduct a question and answer session after the opening remarks. Instructions will follow at that time.
MMSI RVNC HTFA HRZN HTF TTNP

16
Thérapeutique Knight annonce l’approbation réglementaire canadienne de PROBUPHINE(MC) pour la dépendance aux opioïdes

2018-04-20 globenewswire
MONTRÉAL, 20 avr. 2018 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX:GUD) (« Knight », société pharmaceutique spécialisée et chef de file au Canada, a annoncé aujourd’hui que Santé Canada a approuvé PROBUPHINEMC (implant sous-cutané de buprénorphine) pour la prise en charge de la dépendance aux opioïdes chez le patient dont l’état clinique est stable grâce à la buprénorphine administrée par voie sublinguale à une dose n’excédant pas 8 mg, en association avec un counseling et un soutien psychosocial.
TTNP GUD

16
Knight Therapeutics Announces Canadian Regulatory Approval for PROBUPHINE™ for Opioid Drug Dependence

2018-04-20 globenewswire
MONTREAL, April 20, 2018 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD)(“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Health Canada has approved PROBUPHINE™ (buprenorphine subdermal implant) for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support.
TTNP GUD KHTRF

25
TTNP / Titan Pharmaceuticals, Inc. FORM 8-K (Current Report)

2018-04-13 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TTNP

114
3 Stocks to Watch on Tuesday: Atlas Financial Holdings Inc (AFH), Eastside Distilling Inc (EAST) and Titan Pharmaceuticals, Inc. (TTNP) | InvestorPlace

2018-04-03 investorplace
U.S. stocks plummeted Monday as the tech industry was hit hard and Amazon.com, Inc. (NASDAQ:AMZN) experienced a selloff, falling 5%. The S&P 500 Index fell 2.2%, the Dow Jones Industrial Average slid 1.9% and the Nasdaq Composite fell 2.7%.
AMZN EAST TTNP AFH ESDI EDSI

20
Titan Pharmaceuticals' (TTNP) CEO Sunil Bhonsle on Q4 2017 Results - Earnings Call Transcript

2018-04-03 seekingalpha
Thank you for holding, and welcome to the Titan Pharmaceuticals Fourth Quarter and Full Year 2017 Financial Results Conference Call. [Operator Instructions]. Please be advised that this call is being taped at the company's request and will be archived on the company's website starting later today. At this time, I would like to turn the call over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals.
OPNT TTNP GUD KHTRF

16
TTNP / Titan Pharmaceuticals, Inc. null

2018-04-02 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
TTNP

17
TTNP / Titan Pharmaceuticals, Inc. FORM 10-K (Annual Report)

2018-04-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
TTNP

Related Articles

HIMX: Himax Technologies Analysis and Research Report

13h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

CUSIP: 888314309